 |
|
|
| |
SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN PEDIATRIC PATIENTS 6 TO < 18 YEARS OLD WITH CHRONIC HEPATITIS C INFECTION
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Dr. Maureen M. Jonas1, Dr. Rene Romero2, Dr. Etienne M. Sokal3, Dr. Philip Rosenthal4, Gabriella Verucchi5, Chuan-Hao Lin6, Jessica W. Wen7, Michael R Narkewicz8, Sanjay Bansal9, Jiang Shao10, Chiahsiang Hsueh10, Anuj Gaggar10, Kathryn Kersey11, Regino P Gonzalez-Peralta12, Daniel H. Leung13, Dr. William Balistreri14, Karen F Murray15 and Kathleen B Schwarz16, (1)Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA, (2)Children's Healthcare of Atlanta, Atlanta, GA, USA, (3)Cliniques Universitaires Saint-Luc, Université Catholique De Louvain, Brussels, Belgium, (4)Department of Pediatrics, University of California San Francisco, San Francisco, CA, (5)Azienda Ospedaliero-Universitaria Di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy, (6)Children's Hospital Los Angeles, Los Angeles, CA, (7)The Children's Hospital of Philadelphia, Philadelphia, PA, (8)University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, (9)King's College Hospital, London, United Kingdom, (10)Gilead Sciences Inc., Foster City, CA, (11)Gilead Sciences, Inc., Foster City, CA, (12)Pediatric Gastroenterology, Hepatology and Liver Transplant, Advent Health for Children, Orlando, FL, (13)Baylor College of Medicine and Texas Children's Hospital, Houston, TX, (14)Cincinnati Children's Hospital Medical Center, Cincinnati, OH, (15)University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, (16)Johns Hopkins University School of Medicine, Baltimore, MD
|
| |
|
|
|
|
|
